Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bipolar II Disorder Clear all
Completed Phase 4 Interventional

Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

NCT00181870
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
carbamazepine ER (Equetro)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

NCT02363738
View directory record Official record
Conditions
Bipolar Depression
Interventions
Infliximab, Saline
Drug · Other
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Not applicable Interventional

Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)

NCT00006517
View directory record Official record
Conditions
Seasonal Affective Disorder, Mood Disorders, Depression
Interventions
bright light box, dawn simulator, high-output negative ion generator, low-output negative ion generator, dawn light pulse
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

NCT07116694
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation
Interventions
BXCL501 Sublingual Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Chino, California • Oceanside, California • Orange, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

NCT00812058
View directory record Official record
Conditions
Bipolar I Depression
Interventions
RG2417, Placebo
Drug
Lead sponsor
Repligen Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2011 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression

NCT02600494
View directory record Official record
Conditions
Bipolar Depression
Interventions
ITI-007 (Lumateperone), Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
55
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

Antidepressant Therapy in Treating Bipolar Type II Major Depression

NCT00602537
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Venlafaxine, Lithium Carbonate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Jul 22, 2026, 2:27 PM EDT
Enrolling by invitation No phase listed Observational

MDR - PMCF Study for RingLoc Bipolar Acetabular Cup and Endo II Femoral Heads

NCT05199870
View directory record Official record
Conditions
Hip Arthritis, Hip Disease, Hip Fractures, Hip Injuries, Hip Pain Chronic
Interventions
RingLoc Bipolar Acetabular Cup, Endo II Femoral Head
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder

NCT05340504
View directory record Official record
Conditions
Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder
Interventions
N-Acetyl cysteine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

NCT03156504
View directory record Official record
Conditions
Major Depression, Bipolar I Disorder, Bipolar II Disorder, Unipolar Depression
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Jul 22, 2026, 2:27 PM EDT
Active, not recruiting Not applicable Interventional

Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression

NCT03484494
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Low Field Magnetic Stimulation
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 22, 2026, 2:27 PM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder

NCT04211428
View directory record Official record
Conditions
Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Bipolar Type I Disorder, Bipolar Disorder Mild, Bipolar Disorder Moderate, Bipolar Disorder Severe
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

NCT01750398
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Testosterone cypionate, Goserelin, Leuprolide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 4 Interventional

Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder

NCT00181987
View directory record Official record
Conditions
ADHD, Bipolar Disorder
Interventions
methylphenidate HCl (Concerta)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Jul 22, 2026, 2:27 PM EDT
Recruiting Phase 4 Interventional

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCT07213466
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions
Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 22, 2026, 2:27 PM EDT
Not listed Not applicable Interventional

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness

NCT05705063
View directory record Official record
Conditions
Bipolar Disorder I, Bipolar II Disorder, Bipolar I Disorder, Bipolar Disorder, Bipolar Depression, Bipolar and Related Disorders, Bipolar Disorder, Type 1, Bipolar Disorder, Type 2, Bipolar Disorder, Mixed, Obesity, Metabolic Syndrome, Ketogenic Dieting, Weight Gain, Brain Metabolic Disorder, Psychotropic Agents Causing Adverse Effects in Therapeutic Use
Interventions
LCHF Ketogenic Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 22, 2026, 2:27 PM EDT
Withdrawn Phase 2 Interventional

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

NCT03290963
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Lithium, Placebo, Ketamine
Drug
Lead sponsor
William V. Bobo, M.D.
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 3 Interventional

Bipolar II Depression: Lithium, SSRI, or the Combination

NCT00276965
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Sertraline, Lithium carbonate
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Jul 22, 2026, 2:27 PM EDT
Completed No phase listed Observational

Bipolar Proteomic Assay Validation Study

NCT02746367
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar I and Bipolar II
Interventions
Diagnostic test (LDT)
Other
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Iowa City, Iowa • Minneapolis, Minnesota • Mason, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

Tranylcypromine Treatment of Bipolar Depression

NCT01430455
View directory record Official record
Conditions
Bipolar Disorder I or II
Interventions
Tranylcypromine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Differential Responses to Drugs and Sweet Tastes

NCT03810703
View directory record Official record
Conditions
Bipolar II Disorder
Interventions
Placebo oral capsule, d-amphetamine 10 mg oral capsule, d-amphetamine 20 mg oral capsule
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 19 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 4 Interventional

Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder

NCT00181779
View directory record Official record
Conditions
Bipolar Disorder, Mania
Interventions
aripiprazole (Abilify)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Jul 22, 2026, 2:27 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

NCT00771134
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lu AA39959, Placebo, Quetiapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Jul 22, 2026, 2:27 PM EDT